75N93025C00035↗
Locus Biosciences Inc received this contract from National Institutes of Health Niaid, National Institutes of Health: $7.90M obligated so far for health r&d services; health care services; applied research. It runs to 2029-02-07.
Key facts · data as of Oct 22, 2026
- Recipient
- Locus Biosciences Inc
- Awarding agency
- National Institutes of Health (Department of Health and Human Services)
- Contracting office
- National Institutes of Health Niaid (75N930)
- Obligated to date
- $7.90M
- Potential value
- $27.81M
- Ends
- 2029-02-07
Source: USAspending.gov prime award records (obligations: money committed, not outlays), data as of Oct 22, 2026.
Cite this page: SpendQuery, Award 75N93025C00035, data as of Oct 22, 2026, https://spendquery.com/award?id=CONT_AWD_75N93025C00035_7529_-NONE-_-NONE-
Locus Biosciences Inc: all federal awards · Department of Health and Human Services: spending · National Institutes of Health Niaid: what it buys
ADVANCE A NOVEL THERAPEUTIC TO A FIRST-IN-HUMAN CLINICAL STUDY
What it is
- Product or service
- Health R&D Services; Health Care Services; Applied Research (PSC AN12)
- Industry
- Research and Development in Biotechnology (Except Nanobiotechnology) (NAICS 541714)
- Contracting office
- National Institutes of Health Niaid (75N930)
- Competition
- Full and open competition · 16 offers received
- Pricing
- Cost plus fixed fee
- How it was bought
- Standalone contract
- Where the work is
- Durham, NC · district NC-04
Obligations by fiscal year
SpendQuery holds FY2023 on; earlier years are on USAspending.gov.
Subcontractors: where the money went next
No subawards reported for this award. Primes report subawards of $30,000 or more; many awards have none.
Every action
5 actions since 2025-09-22. Each is a modification or amendment with the money it added or took back.
| Date | Modification | Kind | Amount | What the agency wrote |
|---|---|---|---|---|
| 2026-08-26 | P00004 | Administrative change | $0 | EO 14398 ADVANCE A NOVEL THERAPEUTIC TO A FIRST-IN-HUMAN CLINICAL STUDY |
| 2026-07-07 | P00003 | Administrative change | $0 | EO 14398 ADVANCE A NOVEL THERAPEUTIC TO A FIRST-IN-HUMAN CLINICAL STUDY |
| 2026-05-11 | P00002 | Option exercised | $4.58M | ADVANCE A NOVEL THERAPEUTIC TO A FIRST-IN-HUMAN CLINICAL STUDY |
| 2026-02-19 | P00001 | Administrative change | $0 | ADVANCE A NOVEL THERAPEUTIC TO A FIRST-IN-HUMAN CLINICAL STUDY |
| 2025-09-22 | 0 | $3.32M | ADVANCE A NOVEL THERAPEUTIC TO A FIRST-IN-HUMAN CLINICAL STUDY |
Source: USAspending.gov prime award transactions and FSRS subaward reports, as loaded by SpendQuery (data as of 2026-10-22). Amounts are obligations (money committed), not outlays. The official record on USAspending.gov ↗